Bosulif 400 MG tablet 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F5RBX
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,904
Award facts
- Contract value 100% obligated
- $24,903.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 27, 2026, the Defense Logistics Agency awarded a delivery order valued at $24,903.72 to AmerisourceBergen Drug Corp for the supply of Bosulif 400 mg tablets (30-count packages). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by February 18, 2026. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement. The company supplies a comprehensive range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Bosulif (bosutinib) is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia, representing the type of specialty oncology medication typically procured through DLA's pharmaceutical supply chain to support military treatment facilities and veterans' healthcare programs globally.
Quick answers
Who was awarded contract SPE2DR26F5RBX?
SPE2DR26F5RBX was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26F5RBX worth?
The government has obligated $24,904 on SPE2DR26F5RBX.
Is contract SPE2DR26F5RBX an order under another contract?
Yes. SPE2DR26F5RBX is a delivery order under SPE2DR25D2013, an indefinite delivery contract.
Was contract SPE2DR26F5RBX competed?
The extent of competition for SPE2DR26F5RBX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award